L
Laura Pala
Researcher at European Institute of Oncology
Publications - 68
Citations - 1742
Laura Pala is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 12, co-authored 47 publications receiving 915 citations. Previous affiliations of Laura Pala include University of Milan.
Papers
More filters
Journal ArticleDOI
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Fabio Conforti,Laura Pala,Vincenzo Bagnardi,Tommaso De Pas,Marco Martinetti,Giuseppe Viale,Richard D. Gelber,Aron Goldhirsch +7 more
TL;DR: Immune checkpoint inhibitors can improve overall survival for patients with advanced cancers, but the magnitude of benefit is sex-dependent, and future research should guarantee greater inclusion of women in trials and focus on improving the effectiveness of immunotherapies in women.
Journal ArticleDOI
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
Pier Francesco Ferrucci,Sara Gandini,Angelo Battaglia,Salvatore Alfieri,A.M. Di Giacomo,Diana Giannarelli,G. C.Antonini Cappellini,F. De Galitiis,Paolo Marchetti,Giovanni Amato,Andrea Lazzeri,Laura Pala,Emilia Cocorocchio,Chiara Martinoli +13 more
TL;DR: Findings show that baseline NLR is strongly and independently associated with outcome of patients treated with ipilimumab, and may serve to identify patients most likely to benefit from this therapy.
Journal ArticleDOI
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Fabio Conforti,Laura Pala,Vincenzo Bagnardi,Giuseppe Viale,Tommaso De Pas,Eleonora Pagan,Elisabetta Pennacchioli,Emilia Cocorocchio,Pier Francesco Ferrucci,Filippo de Marinis,Richard D. Gelber,Aron Goldhirsch +11 more
TL;DR: Women with advanced lung cancer derived statistically significantly larger benefit from the addition of chemotherapy to anti-PD1/PD-L1 as compared with men.
Journal ArticleDOI
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
Alessio Cortellini,Marco Tucci,Vincenzo Adamo,Luigia Stefania Stucci,Alessandro Russo,Enrica Teresa Tanda,Francesco Spagnolo,Francesca Rastelli,R. Bisonni,Daniele Santini,Marco Russano,Cecilia Anesi,Raffaele Giusti,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Mario Occhipinti,Riccardo Marconcini,Maria Giuseppa Vitale,Linda Nicolardi,Rita Chiari,Claudia Bareggi,Olga Nigro,Alessandro Tuzi,Michele De Tursi,Nicola Petragnani,Laura Pala,Sergio Bracarda,Serena Macrini,Alessandro Inno,Federica Zoratto,Enzo Veltri,Barbara Di Cocco,Domenico Mallardo,Maria Grazia Vitale,David J. Pinato,Giampiero Porzio,Corrado Ficorella,Paolo A. Ascierto +39 more
TL;DR: The association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors is confirmed, which can be assumed to have immune-modulating detrimental effects.
Journal ArticleDOI
The role of systemic therapy in the management of sinonasal cancer: A critical review
Paolo Bossi,Nabil F. Saba,Jan B. Vermorken,Primoz Strojan,Laura Pala,Remco de Bree,Juan P. Rodrigo,Fernando López,Ehab Y. Hanna,Missak Haigentz,Robert P. Takes,Piet J. Slootweg,Carl E. Silver,Alessandra Rinaldo,Alfio Ferlito +14 more
TL;DR: The treatment of SNC requires a multimodal approach, and employment of systemic therapy for locally advanced disease could result in better outcomes, and optimize the therapeutic armamentarium.